Compositions and methods disclosed herein can help provide improved delivery of non-natural therapeutic nucleotides for the treatment of diseases such as cancer. An example composition includes an assembly of amphiphilic polynucleotides, where each amphiphilic polynucleotide includes an aptamer portion, a first nucleotide portion, and a second nucleotide portion.

Compositions and methods disclosed herein can help provide improved delivery of non-natural therapeutic nucleotides for the treatment of diseases such as cancer. An example composition includes an assembly of amphiphilic polynucleotides, where each amphiphilic polynucleotide includes an aptamer portion, a first nucleotide portion, and a second nucleotide portion.

Disclosed is an agent capable of inhibiting the activity or enhancing expression of various cancer-related RNAs in TAMS and cancer cells. Disclosed is also a dual-targeted drug delivery system capable of binding to both tumor cells and macrophages in which the PD-L1 receptor is overexpressed.

The invention provides an S1P ligand-binding nucleic acid complex that is delivered to a target organ to regulate expression or editing of a target gene or a transcription or translation product thereof. The S1P ligand-binding nucleic acid complex includes a nucleic acid with an antisense oligonucleotide 12 to 30 nucleotides in length, and has a nucleic acid sequence complementary to a target transcription product, bound to a S1P ligand. The nucleic acid complex is useful for the treatment of a disease caused by such gene. The ligand-binding nucleic acid complex can be delivered to an organ, tissue, or cell in which the S1P receptor is expressed, such as the skeletal muscle, cardiac muscle, liver, kidney, lung, mammary gland, fat, podocyte, lymphocyte, or vascular endothelial cell.

The invention pertains to modifications for antisense oligonucleotides, wherein the modifications are used to improve stability and provide protection from nuclease degradation. The modifications could also be incorporated into double-stranded nucleic acids, such as synthetic siRNAs and miRNAs.

Synthetic genetic polymers (XNAs) have the potential to transition aptamers from laboratory tools to therapeutic agents, but additional functionality is needed to compete with antibodies. The present invention features compositions and methods that utilizes a biologically stable artificial genetic system comprised of -L-threofuranosyl nucleic acid (TNA). This system facilitates the production of backbone- and base-modified aptamers termed threomers that function as high quality protein capture reagents.

Synthetic genetic polymers (XNAs) have the potential to transition aptamers from laboratory tools to therapeutic agents, but additional functionality is needed to compete with antibodies. The present invention features compositions and methods that utilizes a biologically stable artificial genetic system comprised of -L-threofuranosyl nucleic acid (TNA). This system facilitates the production of backbone- and base-modified aptamers termed threomers that function as high quality protein capture reagents.

The present disclosure provides oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one modified internucleoside linking group.

The present disclosure provides oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one modified internucleoside linking group.